title: Interview with Sanofi's Dr Tunde Falode.
abstract: Dr Tunde Falode speaks to Elena Conroy, Commissioning Editor: Dr Tunde Falode is General Manager for the Diabetes and Cardiovascular Business Unit in the UK and Ireland at Sanofi, a global pharmaceutical company. Following graduation from the University of Jos Medical School in Nigeria, he secured a basic surgical training post through Guy's and St Thomas' hospitals in London, eventually specializing in cardiac and thoracic surgery, before changing his career path. In addition to his current role at Sanofi, he recently completed his specialist training in pharmaceutical medicine and has a keen interest in sports.
authors.affiliation: Diabetes & Cardiovascular Business Unit, Sanofi, Surrey, UK.
authors.forename: Tunde
authors.initials: T
authors.lastname: Falode
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002309:Cardiology / Q000639:trends*; D002322:Career Mobility; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry; D006333:Heart Failure / Q000628:therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D009549:Nigeria; D013903:Thoracic Surgery; D006113:United Kingdom
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C571059:alirocumab
keywords: PCSK9i; Sanofi; Tunde; alirocumab; apheresis; cholesterol; familial hypercholesterolaemia; high cholesterol; praluent; statin